News

Investing19d
Silexion advances dual-route strategy for KRAS cancer therapy
GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced an ...
Investing20d
Silexion advances dual-route strategy for KRAS cancer therapy
GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced ...
Yahoo Finance20d
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...
manilatimes20d
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
SLXN) ("Silexion” or the "Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced an expanded development plan for its ...